Dec 31, 2020
In this Encore episode, Stacey Richter talks with Chris Sloan, associate principal at Avalere Health, about how Medicare Part D plans became addicted to drug rebates — and what happens to premiums, PBMs, and pharma pricing if a proposal to eliminate those rebates actually takes effect.
WHAT YOU’LL LEARN
✅ Why rebates are such a big part of how Medicare Part D actually functions
✅ How rebates flow between PBMs and manufacturers, and how list prices factor in
✅ Why killing pharma rebates would likely raise everybody’s insurance premiums under the current model
✅ Why PBMs and health plans oppose eliminating rebates while pharma supports it
✅ How large PBMs can create perverse incentives that push manufacturers to raise list prices
WHY THIS MATTERS
A reboot of a proposal to eliminate pharma manufacturer rebates to Part D plans and PBMs was set to take effect 1/1/2022, and Chris Sloan breaks down what’s actually at stake: removing rebates could upend the historically opaque middle layer of drug pricing, but the immediate effect — under how the system is built today — is that premiums go up. That tension is exactly why PBMs and health plans line up against the proposal while pharmaceutical manufacturers back it.
=== LINKS ===
🔗 Show Notes with all mentioned links: Episode Page
🔗 Healthcare Industry Acronyms and Terms
✉️ Enjoy this podcast? Subscribe to the free weekly newsletter
🫙 Support the podcast with a small donation to the Tip Jar
📺 Subscribe to our YouTube channel
🎤 Listen on Apple Podcasts
🎤 Listen on Spotify
=== CONNECT WITH THE RHV TEAM ===
✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X
00:00 Introduction
02:35 “Rebates are a really big part of Medicare Part D.”
02:49 What the “follow the dollar” looks like in this scenario.
04:14 How rebates between PBMs and manufacturers work, and how list prices play into this.
05:31 How this system can hurt the patient, and how this new proposal works to change that.
06:42 Pricing a product as a PBM.
08:06 The total dollar value of PBM rebates.
10:50 Do we know how much PBMs are making in incentives?
13:29 Are PBMs helping or hurting the process?
16:18 Why pharmaceutical manufacturers may be more compelled to raise their prices thanks to large PBMs.
17:13 Perverse incentives in the system.
17:57 “At the end of the day, PBMs are still going to be employed by health plans.”
18:56 How a new model is combating the perverse incentive that raises prices for patients.
22:11 The trade-off involving premium prices in this new proposal.
24:38 “We’re not talking astoundingly large amounts of money.”
25:12 Why PBMs and health plans are against this proposal.
26:02 Why Pharma is for this.
26:51 The perverse incentives for health plans.
28:39 The benefit of Part D.
29:25 The advantage of huge rebates.